HR23B, a biomarker for HDAC inhibitors
<p>As our understanding of cancer biology increases and novel therapies are developed, an increasing number of predictive biomarkers are becoming clinically available. Aberrant acetylation has been strongly linked to tumourigenesis and the modulation of acetylation through targeting histone d...
Autor principal: | Khan, OA |
---|---|
Outros Autores: | La Thangue, NB |
Formato: | Thesis |
Idioma: | English |
Publicado em: |
2013
|
Assuntos: |
Registos relacionados
-
Mitochondrial modulators of hypoxia-related pathways in tumours
Por: Snell, CE
Publicado em: (2013) -
Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
Por: New, M
Publicado em: (2014) -
Angiogenesis in human lung tumours
Por: Ferguson, ML
Publicado em: (2008) -
Risk factors for haemorrhage in patients with haematological malignancies
Por: Estcourt, LJ
Publicado em: (2014) -
Regulation of stemness and differentiation in colorectal cancer
Por: Gandhi, S
Publicado em: (2010)